Skip to main content

Table 5 Comparison of efficacy of the two treatment options groups

From: Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report

Treatment options Cases ORR% CR/n CR%
Bortezomib-containing regimens 39 94.9 61.51
Thalidomide-containing regimens 22 86.4 18.2
P value   P > 0.05 P = 0.001
  1. Comparison of bortezomib-containing regimens and thalidomide-containing regimens treatment options. There were significant difference (P = 0.001) in CR/nCR and no significant difference in ORR